St. Louis Trust Co - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
St. Louis Trust Co ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$260,450
-17.7%
5,0000.0%0.05%
-15.5%
Q2 2023$316,600
+16.9%
5,0000.0%0.06%
+7.4%
Q1 2023$270,750
+2.3%
5,0000.0%0.05%
-3.6%
Q4 2022$264,600
-7.2%
5,0000.0%0.06%
-9.7%
Q2 2022$285,000
-6.9%
5,0000.0%0.06%
-6.1%
Q1 2022$306,000
-54.6%
5,000
-61.1%
0.07%
-53.5%
Q4 2021$674,000
+230.4%
12,870
+157.4%
0.14%
+178.4%
Q2 2021$204,000
-99.1%
5,000
-99.4%
0.05%
-99.2%
Q2 2020$22,617,000
+67.0%
881,0560.0%6.77%
+32.4%
Q1 2020$13,542,000881,0565.12%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders